MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro by unknown
Chung et al. Stem Cell Research & Therapy 2013, 4:88
http://stemcellres.com/content/4/4/88RESEARCH Open AccessMicroRNA-21 promotes the ovarian
teratocarcinoma PA1 cell line by sustaining
cancer stem/progenitor populations in vitro
Wei-Min Chung1,2†, Wei-Chun Chang2†, Lumin Chen2,3, Ying-Yi Chang2, Chih-Rong Shyr2,4, Yao-Ching Hung1,2*
and Wen-Lung Ma1,2*
See related commentary by Kang, http://stemcellres.com/content/4/5/110Abstract
Introduction: Resistance of cancer stem/progenitor cells (CSPCs) to chemotherapy can lead to cancer relapse.
Ovarian teratocarcinoma (OVTC) arises from germ cells and comprises pluripotent cells that can be used to study
cancer cell stemness. In this study, we evaluated whether microRNA-21 (miR-21) promotes ovarian teratocarcinoma
by maintaining cancer stem/progenitor populations.
Methods: The lentiviral delivery system was used to upregulate or to suppress the expression of miR-21 in the
human ovarian teratocarcinoma cell line PA1 and cell growth assays were used to monitor the expression of
miR-21 at different time points. Antibodies directed toward CD133, a stem cell marker, were used to identify CSPCs
in the PA1 cell population, and the level of miR-21 expression was determined in enriched CSPCs. Stem cell
functional assays (sphere assay and assays for CD133 expression) were used to assess the effects of miR-21 on
progression of the CD133+ population.
Results: Knockdown of miR-21 in PA1 cells attenuated growth of PA1 cells whereas overexpression of miR-21
promoted cell growth. Moreover, knockdown of miR-21 resulted in a marked reduction in the CD133+ population
and sphere formation of CSPCs. In contrast, overexpression of miR-21 resulted in a marked increase in the
population of CD133+ cells as well as sphere formation of CSPCs.
Conclusions: MicroRNA-21 plays a significant role in cancer growth by regulating stemness in cancer cells.
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MicroRNAs (miRs) are small non-coding RNAs (22
to 24 nucleotides in length) that negatively regulate
post-transcription by binding to the 3′UTR of target
messenger RNA [1-4]. Studies have shown that miR-21
functions as an onco-miR by regulating tumorigensis
and tumor progression [5-7] and has been found to
be frequently up-regulated in cancer stem/progenitor* Correspondence: ych6375@gmail.com; maverick@mail.cmu.edu.tw
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reproduction in any medium, provided the orcells (CSPCs) [8-11]. Several studies have demonstrated
that knockdown of miR21 inhibits cell proliferation,
migration and tumor growth in breast [12-14] and ovarian
cancers [15,16]. Furthermore, some reports have shown
that up-regulation of miR-21 maintains self-renewal and
pluripotency of CSPCs and also regulates epithelial-
mesenchymal transition (EMT) in breast cancer stem-like
cells [17,18]. However, it is still unclear whether miR-21
promotes cancer by maintaining the pluripotency of stem
or progenitor cells.
Ovarian cancer can be grouped by cellular origin, in-
cluding epithelial cells (ovarian carcinoma), stromal cells
(ovarian adenoma) and germ cells (ovarian teratoma and
teratocarcinoma (OVTC)) [19,20]. OVTC is a rare,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with those of embryonal carcinoma or choriocarcinoma
[21-25]. OVTC is caused by the abnormal development
of pluripotent germ and embryonic cells, making it a
good model for studying the behavior of CSPCs.
CSPCs are thought to be a confounding factor for tumor
recurrence and chemoresistance because of their capacity
for unlimited self-renew and differentiation [19,26-29].
Studies have shown that several glycoproteins, namely
CD133, CD117, CD24 and CD44, as well as the transcrip-
tion factors OCT-4 and Nanog are markers of CSPCs
[30-34]. CD133 is abundantly expressed in the human
OVTC cell line PA1 and is frequently used to enrich
CSPCs in studies of cancer stem cell characteristics. In
addition to measuring CSPCs markers, tumor sphere
formation is also used to detect and enrich CSPCs [19,27].
Recently, lentiviral-based miRNAs delivery systems
(antisense-miRNAs to knockdown, or pre-miRNAs to
overexpress) were developed to manipulate miRs expres-
sions in cells. By introducing MiRZip-21 microRNA (knock-
down) and pre-miR-21 (overexpression), we established a
durable and effective miR-21 manipulation method [35,36].
In this study, lentiviral-based miR-21 modulators were used
to examine the role of miR-21 in OVTC cells.
Methods
Cell culture
The human OVTC cell line PA1 and the human embry-
onic kidney cell line HEK293T were cultured in ((D)
MEM) (Gibco, USA) with 10% FCS and 1% penicillin/
streptomycin (Gibco, USA). PA1 cells were provided cour-
tesy of >Dr. Min-Chie Hung (MD Anderson, Houston, TX,
USA) and HEK293T cells were obtained from Dr. Yuh-
Pyng Sher (Center of Molecular Medicine, China Medical
University Hospital, Taichung, Taiwan). The cell lines were
maintained at 37°C in a humidified atmosphere of 5% CO2.
Western blotting assay
Protein extraction and the immunoblot assay were
performed as previously described [37]. Briefly, cells were
washed with 1 x PBS and resolved in RIPA buffer (100 mM
Tris, 5 mM ethylenediaminetetraacetic acid (EDTA), 5%
NP40; pH8.0) with protease inhibitors (1 mM phenylmethyl
sulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin).
Proteins were resolved by SDS-PAGE and then transferred
to polyvinylidene difluoride (PVDF) membranes. Blocking
of non-specific binding was accomplished by adding 5%
non-fat milk. After application of primary antibodies, sec-
ondary antibodies were applied (1:3,000, horseradish perox-
idase (HRP)-goat-anti-mouse and HRP-goat-anti-rabbit) for
one hour at room temperature. Signals were enhanced
using an enhanced chemiluminescence kit (Millipore,
Billerica, Massachusetts 01821, USA) and detected by
ChemiDoc ™ XRS + (BioRad, Hercules, CA 94547).Transfection and infection procedure
Basically, the lentiviral production and infection procedures
were carried out as reported previously [38]. Briefly, cells
were transfected with the following lentivirus plasmids:
psPAX2 packaging plasmid, pMD2G envelope plasmid
(Addgene, Cambridge MA 02139) [37,38], miRZip-21 [35]
(anti-miR-21 microRNA construct; System Biosciences,
SBI, Johnstown, PA 15901, USA), and hsa-miR21 [36] (Hu-
man Lentiviral Primary microRNA Over-Expression Con-
struct in pMIRNA1; System Biosciences, SBI). Both
lentiviral plasmids carried the GFP gene and were co-
transfected with psPAX2 and pMD2G into HEK293T cells
at a ratio of 3:2:4 by lipofectamine2000 (Invitrogen, USA)
as per the manufacturer’s instructions. After six hours, the
medium was replaced with fresh (D)MEM/10% fetal bovine
serum (FBS) medium and cells were maintained at 37°C in
a humidified incubator in an atmosphere of 5% CO2 for 48
hours. Medium containing virus was collected by centrifu-
gation and filtered through a 0.45 μm filter. Medium
containing 0.8 mg/ml polybrene (Sigma-Aldrich, USA) was
then added to culture dishes containing 106 PA1 cells. After
16 hours of infection, the medium containing virus was re-
placed with fresh (D)MEM/10% FBS medium and cells
were maintained at 37°C in a humidified incubator in an at-
mosphere of 5% CO2 for 48 hours. Infected cells were then
collected and analyzed. The GFP+ cells were measured by
flow cytometry (BD LSR II Flow Cytometry) to determine
infection efficiencies. GFP + cells with infection efficiencies
greater than 85% were subjected to the following experi-
ments (data not shown).
Total RNA isolation and cDNA synthesis
RNA was extracted from PA1 cells as reported previously
[37]. Briefly, cells that had reached approximately 80% to
90% confluence in 100-mm dishes were lysed with 1 ml
Trizol (Invitrogen). Phenol/chloroform was then added and
RNA-rich layers were separated by centrifugation. Soluble
RNA was precipitated with 2-propanol. RNA was then
rinsed with 75% ethanol and dissolved in RNase-free water.
For first-strand cDNA synthesis, 5 μg of total RNA was
used to perform reverse transcription PCR by the
PrimeScript™ RT reagent kit (Takara Bio Inc., Tokyo, Japan).
MiRNA cDNA was synthesized using the Mir-X™ miRNA
First-Strand synthesis Kit (Clontech, Mountain View, CA
94043, USA). cDNA and miRNA were synthesized
according to the manufacturer’s instructions.
Quantitative real-time PCR analysis
A real-time detection system (Bio-Rad Laboratories,
Inc., Hercules, CA, USA) and the KAPA™ SYBR FAST
One-Step qRT-PCR Kit (Kapa Biosystems, Woburn,
MA, USA) were used according to the manufacturers’
instructions. Relative gene expression was determined by
normalizing the expression level of the target gene to
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Threshold value (Ct) dynamics were used (2-ΔΔCt) for
quantitation of gene expression. The qRT-PCR primer
sequences were as follows: CD133 forward 5′- TCT
CTA TGT GGT ACA GCC G-3′, reverse 5′- TGA TCC
GGG TTC TTA CCT G-3′; CD24 forward 5′- TTT
ACA ACT GCC TCG ACA CAC ATA A-3′, reverse 5′-
CCC ATG TAG TTT TCT AAA GAT GGA A-3′; CD44
forward 5′- GAC CTC TGC AAG GCT TTC AA-3′, re-
verse 5′- TCC GAT GCT CAG AGC TTT CTC-3′;
CD117 forward 5′- CAA GGA AGG TTT CCG AAT
GC-3′, reverse 5′- CCA GCA GGT CTT CAT GAT GT-
3′; Nanog forward 5′- GGG CCT GAA GAA AAC TAT
CCA TCC-3′, reverse 5′- TGC TAT TCT TCG GCC
AGT TGT TTT-3′; OCT-4 forward 5′- GGC CCG
AAA GAG AAA GCG AAC C-3′, reverse 5′- ACC
CAG CAG CCT CAA AAT CCT CTC-3′; SCF forward
5′- ACT GAC TCT GGA ATC TTT CTC AGG-3′, re-
verse 5′- GAT GTT TTG CCA AGT CAT TGT TGG-
3′; miR-21 5′- TAGCTTATCAGACTGATGTTGA-3′.Figure 1 Knockdown of miR-21 inhibits PA1 cell growth. MiR-21 expre
(miR-21 KD) than in cells infected with control (miR-lentivector) constructs.
PCR and the relative amount of miR-21 is presented as the values of 2-ΔΔC
infected PA1 cells. Images were photographed on the sixth day of culture
WST-1 assays were performed at the indicated time points (one, two, four,
the absolute absorbance (Abs.) values (Abs. at 450 nm deducted from Abs.
reproducible experiments (C). * indicates significance at P values less thanCell growth analysis
The WST-1 assay (Roche, Indianapolis, Indiana 46250,
USA) [39] was used to assess cell growth. Briefly, 103 cells/
100 μl/well were seeded in 96-well plates with (D)MEM in
10% FBS and were incubated for the designated time
periods (one, two, four, six and eight days). Then 10 μl of
WST-1 solution was added to each well and cells were
allowed to incubate at 37°C in an incubator for one hour.
Cell viability was quantified by colorimetric detection in an
ELISA plate reader (Beckman Coulter Paradigm™ Detec-
tion Platform, USA) at an absorbance of 450 nm and 690
nm to generate an optical density (OD) proportional to the
relative abundance of live cells in the given wells.
Verification and sorting of CD133+ cells
Cells were detached with 1% trypsin/EDTA and cell mem-
brane non-specific binding to antibodies was blocked by
5% BSA for 30 minutes at room temperature. Cells were
then incubated with antibody CD133- allophycocyanin
(APC) (magnetic cell separation (MACS), Miltenyi Biotec,ssion was significantly lower in PA1 cells infected with anti-miR-21
Relative expression of miR-21 was detected with quantitative real-time
t (A). Cell morphology and confluence of vector- or anti-miR-21-
using a phase contrast fluorescence microscope (40×) (B). Cell growth
six and eight days) and are shown on the X-axis. The Y-axis indicates
at 630 nm background readings). The results shown are from three
0.05. miR, microRNA.
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flow cytometry (fluorescence-activated cell sorting (FACS),
BD FACSAria, USA) analysis. The CD133+/− cells were
collected by a cell sorter (BD FACSAria).
Sorting of CD133+ and CD133– populations
A CD133 MicroBead kit (Miltenyi Biotec) was used to
sort PA1 CD133+ cells according to the manufacturer’s
instructions. Briefly, 108 cells were washed, resuspended
in 300 μl of buffer (1 X PBS/ pH 7.2, 0.5% BSA/2 mM
EDTA), with 100 μl FcR Blocking Reagent and 100 μl of
CD133 MicroBeads, mixed well, and then incubated for
30 minutes at 2°C to 8°C. The labeled cells were then
washed, resuspended in 500 μl buffer and applied on a
MACS Column of MiniMACS separation kit to collect
the unlabeled negative fraction (that is, CD133– cells).
Finally, we moved the column onto collection tubes to
collect labeled cells (that is, CD133+ cells).
Sphere formation assay
Cells were collected and washed to remove serum and
then suspended in serum-free (D)MEM supplementedFigure 2 Overexpression of miR-21 promotes PA1 cell growth. MiR-21
(miR-21 OE) than in cells infected with control (miR-cGFP vector) constructs. R
and the relative amount of miR-21 is presented as the value of 2-ΔΔCt (A). Cel
Images were photographed on the fourth day of culture using a phase co
were performed at the indicated time points (one, two, four, six and eight
absorbance (Abs.) values (Abs. at 450 nm deducted from Abs. at 630 nm b
experiments (C). * indicates significance at P values less than 0.05. miR, miwith 20 ng/ml human recombinant epidermal growth
factor (hrEGF), 10 ng/ml human recombinant basic
fibroblast growth factor (hrbFGF), 5 μg/mL insulin and
0.4% BSA (Sigma). The cells were subsequently cul-
tured in ultra low attachment 6-well plates (Corning
Inc., Corning, NY, USA) at a density of less than 5,000
cells/well for 14 days. Spheres were observed under
a microscope and images were photographed under
a phase contrast fluorescence microscope (Nikon,
ECLIPSE 80i).
Statistical analysis
Statistical analyses were performed using the Student’s t-
test. All experiments were repeated at least three times,
and P-values less than 0.05 were considered to indicate
statistical significance.
Results
MiR-21 is essential for PA1 cell growth
Knockdown of miR-21 has been shown to inhibit cell
growth in ovarian cancer in vitro [15,16]. To assess
whether miR-21 affects cell growth in OVTC, we usedexpression was significantly higher in PA1 cells infected with pre-miR-21
elative expression of miR-21 was detected with quantitative real-time PCR
l morphology and confluence of vector- or pre-miR-21-infected PA1 cells.
ntrast fluorescence microscope (40×) (B). Cell growth WST-1 assays
days) and are shown on the X-axis. The Y-axis indicates the
ackground readings). The results shown are from three reproducible
croRNA; OE: overexpression.
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constructs. We found that miRZip-21 reduced miR-
21 expression levels by 85% in PA1 cells (Figure 1A).
We measured the effects of miR-21 knockdown on
PA1 cell growth at days one, two, four, six and eight
and found that cell numbers had diminished at day
six of culture (Figure 1B). As seen in Figure 1C, cell
growth was abolished by miR-21 knockdown during
all measurement time points. These data suggest that
miR-21 is essential for OVTC PA1 cell growth, a find-
ing consistent with that reported in previous studies
[12-16].Figure 3 MiR-21 was up-regulated in CD133+ PA1 cell populations. A
sorting. The basal IgG-isotype-APC staining signal peaks are presented on t
presented on the right-hand side of the histogram. As indicated in P2 and
sorted. Negatively stained cells (P2, left-hand side 5%) were defined as CD1
as CD133+ cells (A). CSPC marker genes were examined using quantitative
calculated as 2-ΔΔCt. The expression of Nanog, OCT-4, CD117, CD44, CD24,
CD133+ cells. (B). MiR-21 expressed in CD133+ and CD133– cells. Quantita
Expression of miR-21 in CD133– cells (basal level) was compared with the l
(C) represent the mean of three individual sets of experiments. The variatio
statistical significance at P-values less than 0.05. APC, allophycocyanin; CSPC
sorting; IgG, immunoglobulin G; MiR, micro RNA.Exogenous delivery of miR-21 promotes PA1 cell growth
In order to confirm that miR-21 promotes cell growth,
hsa-miR21 plasmids (miR-21 overexpression constructs)
were introduced to overexpress miR-21 in PA1 cells.
In our delivery system, miR-21 expression levels were
approximately twice as great as those in the vector con-
trol (Figure 2A). As expected, PA1 cells treated with
pre-miR-21 had higher growth capacity compared to
vector control delivery at day four (Figure 2B). As seen
in Figure 2C, cell growth was enhanced by miR-21
overexpression during all measurement time points. This
result is consistent with the data presented in Figure 1.PC-conjugated CD133 antibody was used to enrich CSPCs by FACS
he left-hand side and the CD133-APC staining signal peaks are
P3, the 5% extremes of the staining signal within the spectrum were
33- and positively stained cells (P3, right-hand side 5%) were defined
real-time PCR, and the relative amount of each CSPC marker was
and CD133 in CD133– cells was compared with that of each gene in
tive real-time PCR was performed to detect expression of miR21.
evel of expression of miR-21 in CD133+ cells (C). The data in (B) and
ns were from the calculation of standard deviation, and * indicates
s, cancer stem/progenitor cells; FACS, fluorescence-activated cell
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cell growth.
MiR-21 is up-regulated in PA1 CD133+ cells
CD133+ PA1 cells were sorted for further analysis. We
gated the 5% extremes of the CD133 staining signal
spectrum and defined them as CD133– (P2) and CD133+
(P3) cells (Figure 3A). To confirm that the collected cell
population represented CSPCs, CD133 expression levels
and other stem cell markers were examined using quanti-
tative real-time PCR (qRT-PCR) (Figure 3B). We found
that the expression of CD133 and other stem cell markers
was higher in CD133+ cells than in CD133– cells,
which suggests that isolated CD133+ cells exhibit
CSPC characteristics. We also found that miR-21 levels
were higher in CD133+ cells than in CD133– cells
(Figure 3C). This finding indicates that miR-21 pro-
motes PA1 cell growth by maintaining CD133+ CSPCs
populations.Figure 4 MiR-21 is essential for PA1 CSPCs self-renewal. Flow cytomet
side) and CD133-APC (right-hand side) in PA1 cells. Panel A shows the com
and in anti-miR21-infected PA1 cells (lower panel). Sphere formation assay
sphere). The sphere colony images were taken under a phase contrast fluo
vector-infected cells and the image on the right-hand side indicates anti-m
IgG-APC in PA1 cells (left-hand side) were compared with those of CD133-
infected PA1 cells (upper panel) were compared with those in pre-miR21-in
the PA1 cell colonies (black arrows indicate the tumor sphere). The sphere
microscope (40×). The image on the left-hand side indicates vector-infecte
pre-miR21-infected PA1 cell sphere colonies (D). The scale bar represents 2
immunoglobulin G; miR, microRNA.MiR-21 promotes PA1 CSPC self-renewal
Functional assays were performed to confirm the effects
of miR-21 on PA1 CSPCs. As seen in Figure 4A, miR-21
knockdown resulted in a marked reduction in CD133
populations compared with vector-infected PA1 cells
(Figure 4A). We also found that knockdown of miR-21
resulted in little sphere formation compared with vector-
infected controls after 14 days of culture (Figure 4B; black
arrows indicate the tumor sphere). On the contrary,
overexpression of miR-21 resulted in an increase in
CD133 populations (Figure 4C) and CSPC sphere forma-
tion (Figure 4D; black arrows indicate the tumor sphere).
Taken together, these data indicate that miR-21-related
PA1 cell growth is mediated by CSPCs.
MiR-21 is required for maintaining PA1 CD133+ CSPC
To further prove that miR-21 is essential for CSPC
growth and maintenance of its population, we evaluated
sphere formation of CD133– and CD133+ cells that hadric signal intensities were used to compare isotype-IgG-APC (left-hand
parison of CD133+ populations in vector-infected cells (upper panel)
images of the PA1 cell colonies (black arrows indicate the tumor
rescence microscope (40×). The image on the left-hand side indicates
iR21-infected PA1 cell sphere colonies (B). Signal intensities of isotype-
APC in PA1 cells (right-hand side). CD133+ populations in vector-
fected PA1 cells (lower panel) (C). Sphere formation assay images of
colony images were taken using a phase contrast fluorescence
d cell sphere colonies and the image on the right-hand side indicates
00 μm. APC, allophycocyanin; CSPCs, cancer stem/progenitor cells; IgG,
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miR-21. CD133+/− cells were sorted using CD133
antibody-coated magnetic beads. The results of flow cy-
tometry revealed that efficient gene transduction oc-
curred in approximately 95% of PA1 cells (Figure 5A).
We used qRT-PCR to detect expression of miR-21 in
CD133– and CD133+ populations (Figure 5B). As seenFigure 5 MiR-21 is required for PA1 CD133+ CSPC function. Purified C
cGFPvector and miR-21 OE were collected and the percentage of green flu
percentage of green fluorescence expression of infected cells was compare
non-infected cells were compared with those of infected cell populations (
fluorescence are presented on the right-hand side (A). The relative express
quantitative real-time PCR. Expression of miR-21 in CD133– cells (basal leve
Sphere formation assay images of the CD133+ and CD133– population col
fluorescence microscope (100×). The images in the upper panel indicate ve
indicate anti-miR21-infected cells. The images of visible light and green flu
side) and those on the right-hand side indicate miR21 overexpression (C).
(A) and (B) represent the mean of three individual sets of experiments. The
bar represents 50 μm. CSPC, cancer stem/progenitor cell; KD: knockdown min Figure 5B, miR-21 KD: knockdown (upper panel) led
to a marked decrease in the expression of miR-21 and
miR-21 OE: overexpression (lower panel) resulted in a
marked increase in expression of miR-21. In order to
test the hypothesis that miR-21 is essential for
maintaining the CD133+ pluripotency of OVTC cells,
we performed a sphere formation assay. We first usedD133– and CD133+ populations from miR-lentivector, miR-21 KD, miR-
orescence expression was detected by flow cytometry. The
d with that of non-infected cells. Flow cytometric signal intensities of
left-hand side). The percentages of infected cells with green
ion of miR-21 in CD133+ and CD133– cells was detected using
l) was compared with that of miR-21 expression in CD133+ cells (B).
onies. The sphere colony images were taken under a phase contrast
ctor-infected cells (left-hand side) and those on the right-hand side
orescence in the lower panel indicate vector-infected cells (left-hand
The right panel represents quantitation of sphere diameters. Data in
variations were from the calculation of standard deviation. The scale
iR, microRNA; OE.
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ure 5A and B) and the results revealed satisfactory infec-
tion efficiency. We then sorted CD133−/+ cells for the
sphere formation assay (Figure 5C). As shown in Fig-
ure 5C, CD133+ cells formed more spheres than
CD133– cells in the miR-lentivector- and miR-cGFP
vector-infected groups (Figure 5C, left panel). Knock-
down or overexpression of miR21 in CD133– cells
exerted minor effects on PA1 sphere formation (first and
third row), but suppressed (second row) or enhanced
(fourth row) PA1 sphere formation in CD133+ cells, re-
spectively. The quantified sphere sizes are shown on the
right-hand side of Figure 5C.
Taken together, our results indicate that miR-21 is re-
quired for the maintenance of pluripotency of OVTC
PA1 cells.
Discussion
MiR21 promotes cancer growth and progression
Studies have shown that miRNAs negatively regulate
post-transcription in a variety of gene sets and are asso-
ciated with proliferation, differentiation and progression
in various cancers [1-7]. MiR-21 is up-regulated in dif-
ferent kinds of tumors, including breast and ovary
[8-16]. Although several studies have indicated that
miR-21 expression is high in CSPCs [6-11], the roles
that miR-21 plays in CSPCs are still unclear. Herein we
have shown that knockdown of miR-21 attenuated PA1
cell growth and that overexpression of miR-21 promoted
cell growth.
A number of studies have shown that CD133 is a
marker of cancer stem/progenitor cells [30,40,41], and
functional assays of CSPCs have revealed that enriched
CD133 subpopulations from ovarian cancer tissue are
indeed CSPCs [30,40-44]. By manipulating miR-21 levels
in the cells, we found that miR-21 is required for main-
tenance of CD133 populations. Although this finding is
consistent with that reported in a previous study [8], it
has never been shown in OVTC cells.
Tumor cells with CSPC characteristics grown in
suspended conditions with serum-free stem cell culture
medium can form tumor spheres [27,29]. The sphere
formation assay is widely used to evaluate the self-
renewal ability of cancer stem cells in vitro [19,27,28]. In
addition to testing the effects of miR-21 on characteris-
tics of cancer progenitor cells, we also examined the
self-renewal of CSPCs by conducting a sphere formation
assay and found that miR-21 suppresses PA1 cell growth
by maintaining CD133+ populations.
Chemotherapy resistance might be associated with
miR21-related CSPCs
Chemotherapy resistance and cancer recurrence are
major obstacles in the treatment of cancer. Various miRsare associated with cancer cell proliferation and drug
resistance [41]. Expression of miR-21, for example, has
been demonstrated to be related to chemoresistance in
glioma [45], breast [46,47], bladder [48] and neuroblast-
oma cancer cells [49]. MiR-21 has also been shown to be
linked to resistance to at least nine chemotherapy
agents, for example, temozolomide [41], trastuzumab
[45,46], doxorubicin [47], cisplatin [48], Triptolide [50],
and CHOP (cyclophosphamide, vincristine, Adriamycin,
and prednisone) [51]. Our finding that miR-21 enhances
cancer stemness might explain why this small RNA mol-
ecule is responsible for resistance to so many chemo-
therapeutic agents. In our study, knockdown of miR-21
expression suppressed cell growth and tumor cell
sphere formation. Moreover, we demonstrated that
miR-21 is up-regulated in CD133+ cells (Figure 3C),
indicating that it might be important for the mainten-
ance of CSPC populations. CD133+ cells have been
reported to be associated with drug resistance in glio-
blastoma [52], Ewing sarcoma cells [53], lung cancer
[54,55] and hepatocellular carcinoma [56]. Our find-
ings indicate that miR-21 plays a critical role in regu-
lating CD133+ CSPCs.
Conclusions
Our study revealed that miR-21 regulates CSPCs popula-
tions in PA1 cells. MiR-21, therefore, is a potential target
for cancer therapy, especially in patients with cancer
relapse.
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